Stock analysis posts tagged "medtech" from Openbook.
J&J beat on adjusted EPS and raised full-year guidance, yet the shares closed 5.73% lower at $248.61. MedTech growth of just 2.5% is the reason.
Kevin Lobo hands Stryker to Spencer Stiles on 1 January 2027. The shares fell just 2.46% to $278.20 — and part of that was not the succession at all.
Medtronic's 13.7% organic quarter included about 670bp from a 53rd fiscal week. The underlying rate is near 7%, and that is still the story.
Smith+Nephew fell 3.5% when its CFO quit for Baxter. The turnaround numbers underneath are better than the revenue line suggests — and unfinished.